Navigation Links
Tocagen Expands Clinical Development Team;
Date:8/26/2014

SAN DIEGO, Aug. 26, 2014 /PRNewswire/ -- Tocagen Inc. today announced Wayne Saville, M.D., has been named vice president, clinical development, and Mary Rose Keller has been named vice president, clinical operations.

"As we advance Toca 511 & Toca FC into late-stage registration studies, we are expanding our clinical team with individuals who have deep experience in drug development, regulatory approval, launch and commercialization activities," said Jamey Skillings, M.D., Chief Medical Officer of Tocagen. "Wayne and Mary Rose bring decades of valuable expertise in clinical development and medical affairs at a pivotal time for Tocagen."

Dr. Saville has more than a decade of experience in clinical development and medical affairs for cancer products. Prior to joining Tocagen, he headed medical affairs at Genoptix, an oncology diagnostics laboratory acquired by Novartis. Previous to that position he was a director of clinical research at Amgen, where he led late-stage development of a cancer drug as well as medical affairs for Prolia. Prior to this role, Dr. Saville was the director of oncology clinical research at Biogen Idec, leading clinical and medical affairs programs for Zevalin® and Rituxan®. Previous to this position, he was an associate professor at the University of California, San Diego, and trained in internal medicine at the University of Minnesota Medical Center. He was a medical oncology fellow at the National Cancer Institute and obtained his medical degree and bachelor's degree in medicine at Northwestern University. 

Ms. Keller has more than two decades of experience in drug development and clinical operations, and has worked with numerous research-focused organizations while at University of California, San Francisco's Cancer Research Institute, including the Brain Tumor Research Group, Children's Cancer Study Group and Radiation Therapy Oncology Group. Previously she was the vice president of clinical development and operations at a number of pharmaceutical companies including Prometheus Laboratories and Shire. Prior, she was the senior director of clinical operations at Agouron, leading activities for Viracept®. She subsequently led Agouron's oncology and ophthalmology programs through mergers with Warner-Lambert and Pfizer, ultimately becoming Pfizer's worldwide head development operations, global team leads and clinical trial recruitment services. Ms. Keller also previously worked at New Drug Services, where she participated in eight New Drug Applications. Ms. Keller obtained her bachelor's degree at the University of California, Davis.

About Tocagen Inc.
Tocagen Inc. is a privately funded, clinical stage biopharmaceutical company pursuing the discovery, development and commercialization of gene therapy products for the selective treatment of cancer. Tocagen is initially focusing on treatments for patients with advanced cancer for whom no adequate treatments currently exist. Toca 511 & Toca FC, the company's lead investigational combination product, is being evaluated in three clinical trials in patients with recurrent high grade glioma, including glioblastoma (GBM). Tocagen has received grant support from leading brain cancer foundations, including Accelerate Brain Cancer Cure (ABC2), National Brain Tumor Society (NBTS), American Brain Tumor Association (ABTA), Musella Foundation and Voices Against Brain Cancer (VABC). For more information about Tocagen or Toca 511 please visit www.tocagen.com or www.clinicaltrials.gov using the identifier NCT01470794NCT01156584 or NCT01985256


'/>"/>
SOURCE Tocagen Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer
2. Six Presentations on Tocagens Toca 511 to be Given at the Society of Neuro-Oncology Annual Meeting
3. Data Presented at Society for Neuro-Oncology Annual Meeting Demonstrate Tocagens Toca 511 Gene Therapy with Toca FC was Well Tolerated and Showed Antitumor Activity in Patients with High Grade Glioma
4. As Smartphone Usage Expands, Survey Says Nurses and Nursing Students Want Mobile Access to Credible Drug Data
5. BioSurplus Expands, Debuts New 8000 Square Foot Warehouse and Service Facility
6. RxAlly Expands National Network With Addition Of Nineteen Community Pharmacy Organizations Representing Over 2,000 Pharmacies
7. Clinical Interest in BioElectronics Products Expands to the Wound Care Market
8. S1 Biopharma Expands Focus to Include Male Sexual Health
9. PRA Expands Operations in Europe
10. USANA Health Sciences Expands Award-Winning Research and Development Team
11. Particle Sciences Expands its cGMP Capabilities with the Addition of Thin Films
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... , February 27, 2017 Now ... the pharmaceutical companies that are most successful at developing and ... ... you gave the same molecule to two different companies in ... Based on systematic, objective analysis of each company,s performance ...
(Date:2/27/2017)... -- Period October – December 2016 Revenues ... SEK -16.4 (-6.4) million Result after tax amounted to SEK ... dilution Cash flow from operating activities amounted to SEK -8.3 ... Period full year ... Operating result amounted to SEK -39.5 (-29.5) million ...
(Date:2/24/2017)... Ind. , Feb. 24, 2017 Zimmer ... leader in musculoskeletal healthcare, will present at the Cowen ... at the Boston Marriott Copley Place on Tuesday, March ... A live webcast of the presentation can be ... archived for replay following the conference via Zimmer Biomet,s ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... February 26, 2017 , ... Miro is the ultimate smart media ... system brings songs, movies, TV shows and much more apps for user exploration. Its ... An immersive view of 1280 x 720 provides crisp images with remarkable clarity and ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... mark last week. In addition, Discount Power's RCE (Residential Customer Equivalent) count exceeds ... March 2014. The company had 800 customers and 2,250 RCEs at the time ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... ... hair transplantation therapy, is proud to announce a new informational post on robotic ... procedures. Follicular Unit Extraction (FUE) hair transplant and Follicular Unit Transplantation (FUT) can ...
(Date:2/27/2017)... ... 27, 2017 , ... New Jersey ranks among the top five states in ... the need for advanced services is growing. , Project WE vs C is ... collaboration with their non-profit partners in their fight against cancer and in support of ...
(Date:2/26/2017)... ... February 26, 2017 , ... Today, A' Design ... Edition of International Social Design Awards. , The 7th A' Social Design ... Governments and Institutions worldwide with realized projects and conceptual works. , The first ...
Breaking Medicine News(10 mins):